Bone Health Screening and Treatment in Allogeneic Hematopoietic Stem Cell Transplant (HCT) Patients
Bone density loss is a well-recognized and common complication in allogeneic HCT recipients. Guidelines recommend screening with dual photon densitometry at 1 year post-HCT, and counseling of patients on preventative strategies along with consideration of treatment for patients at high risk for bone loss. However, osteoporosis and fragility fractures remains a major cause of morbidity, and significantly impacts the quality of life of allogeneic HCT survivors. Given the high morbidity of bone density loss in our patients, we sought to create specific guidelines, taking a more proactive approach to bone health within our program.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Christina S. Ferraro, Chad Deal, Theresa A. Urban, Kelly Gaffney, Mariana Lucena, Navneet S. Majhail, Betty K. Hamilton Tags: 100 Source Type: research
More News: Biology | Chad Health | Hematology | Orthopaedics | Osteoporosis | Stem Cell Therapy | Stem Cells | Transplants